Dec 17, 2014 at 22:26 | Source: Moneycontrol.com
Ashok Chawla, chairman, CII has a very clear mantra for companies to follow when it comes to investing in other companies - it's better to ask for permission, than to apologies.
Dec 15, 2014 at 21:14 | Source: CNBC-TV18
As a result of its post merger consultation with the US Federal Trade Commission (FTC), the Sun-Ranbaxy combine will most probably have to sell just one drug for the merger to get the green light.
Dec 15, 2014 at 19:11 | Source: PTI
According to the Competition Commission, the deal, which would create an entity with a combined turnover of over Rs 1,800 crore, is "not likely to have appreciable adverse effect on competition in India".
Dec 13, 2014 at 20:41 | Source: CNBC-TV18
SUN-RANBAXY @ CCI: 1st Structural Remedy!
Dec 11, 2014 at 18:05 | Source: CNBC-TV18
Sun Pharma chairman Israel Makov says the company has started the day after the CCI order. "We are divesting good assets, we are not divesting bad assets and you have a lot of buyers for good assets," he said.
Dec 09, 2014 at 13:24 | Source: Moneycontrol.com
With the cloud of uncertainty vanishing from over the deal, traders can look to exploit an arbitrage opportunity between Sun and Ranbaxy shares.
Dec 09, 2014 at 10:59 | Source: CNBC-TV18
In an interview to CNBC-TV18, Ashok Chawla, Chairperson, CCI, said the order on Sun-Ranbaxy merger is final and that the companies could be given additional 4 months in case the product divestment process exceeds 6 months.
Dec 09, 2014 at 09:34 | Source: Moneycontrol.com
Competition Commission of India (CCI) on Monday cleared the USD 4 billion deal between Sun Pharma and Ranbaxy but with riders.
Dec 09, 2014 at 09:28 | Source: CNBC-TV18
The Competition regulator has given a 6 month window for the divestment process, and only after the divestment is complete will the deal get the final nod. But Surajit Pal believes the divestment process should be done by March.
Dec 08, 2014 at 20:16 | Source: Moneycontrol.com
CCI has asked the two companies to divest some key products along with other changes to the deal to address the anti-competitive issues.